Drawing for ERFLOVO

USPTO serial 85347632

ERFLOVO

Reviewed by CopyMark Law Group

Reg. 4087923Status 710
Filing date
Status date
Registration date
Jan 17, 2012
Examiner
ALI, STEPHANIE MARIE
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with ERFLOVO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Scott D. Woldow

Scott D. Woldow SMITH, GAMBRELL & RUSSELL, LLP1055 Thomas Jefferson St., NWSuite 400WASHINGTON, DC 20007

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of cardiovascular and pulmonary diseases; Pharmaceutical preparations for the treatment of inflammatory diseases; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of auto-immune disorders; Pharmaceutical preparations for the treatment of digital ulcers; Pharmaceutical preparations for the treatment of glycolipid storage diseases; Pharmaceutical preparations for the treatment of cerebrovascular diseases; Pharmaceutical preparations for the treatment of diseases and disorders of the central nervous system and of the peripheral neurological system; Pharmaceutical preparations for the treatment of gastrointestinal disorders; anxiolytics; anti-allergics; anti-infectivesSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 24, 2018C8..CANCELLED SEC. 8 (6-YR)—
Jan 17, 2017REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
May 30, 2013TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 17, 2012R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 1, 2011NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 1, 2011PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 23, 2011PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Sep 16, 2011CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 16, 2011XAECEXAMINER'S AMENDMENT ENTERED—
Sep 16, 2011GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Sep 16, 2011GNEAEXAMINERS AMENDMENT E-MAILED—
Sep 16, 2011CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 13, 2011DOCKASSIGNED TO EXAMINER—
Jul 21, 2011TAEATEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED—
Jul 21, 2011PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Jul 15, 2011AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Jul 7, 2011ALIEASSIGNED TO LIE—
Jul 7, 2011PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Jun 22, 2011NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 20, 2011NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance